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Abstract
Clinical evaluation of immune reconstitution and health status during HIV-1 infection and anti-retroviral therapy (ART) is
largely based on CD4+ T cell counts and viral load, measures that fail to take into account the CD8+ T cell subset, known to
show features of accelerated aging in HIV disease. Here, we compare adenosine deaminase (ADA), glucose uptake receptor
1 (GLUT1), and leucine-rich repeat neuronal 3 (LRRN3) to CD38 expression and telomerase activity, two strong predictors of
HIV disease progression. Our analysis revealed that reduced ADA, telomerase activity and LRRN3 gene expression were
significantly associated with high CD38 and HLA-DR in CD8+ T cells, with % ADA+ cells being the most robust predictor of
CD8+ T cell activation. Our results suggest that ADA, LRRN3 and telomerase activity in CD8+ T cells may serve as novel,
clinically relevant biomarkers of immune status in HIV-1 infection, specifically by demonstrating the degree to which CD8+ T
cells have progressed to the end stage of replicative senescence. Since chronological aging itself leads to the accumulation
of senescent CD8+ T cells, the prolonged survival and resultant increased age of the HIV+ population may synergize with
the chronic immune activation to exacerbate both immune decline and age-associated pathologies. The identification and
future validation of these new biomarkers may lead to fresh immune-based HIV treatments.
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Introduction
Clinical evaluation of immune reconstitution and health status
during HIV-1 infection and anti-retroviral therapy (ART) is
largely based on CD4+ T cell counts and viral load, measures that
provide a somewhat incomplete picture of the true functional
status of the immune system. Specifically, these parameters fail to
consider the state of CD8+ T cells, the subset primarily responsible
for controlling the infection through lysis of HIV-1-infected cells,
release of perforin and granzyme, production of IFN-c and
secretion of soluble factors that suppress HIV-1 replication [1,2].
Since HIV disease involves accelerated immunological aging [3],
research that focuses on a cell population that undergoes
significant changes during chronological aging may provide novel
insights into HIV pathogenesis. Indeed, both HIV disease and
aging involve the accumulation of a population of dysfunctional
CD8+ T cells with characteristics of cellular (replicative) senes-
cence, an end stage characterized by irreversible cell cycle arrest,
multiple genetic and functional changes, and shortened telomeres.
The clinical relevance of this cell population is underscored by
several observations. First, CD8+ T cells with several signature
features of replicative senescence, including reduced anti-HIV
effector functions, permanent suppression of CD28 gene expres-
sion, critically short telomeres, and loss of the ability to upregulate
telomerase, are significantly increased in HIV-1-infected persons,
even in those on ART [4]. Moreover, the abundance of
CD8+CD28- T cells early in the infection is actually predictive
of the subsequent rate of progression to AIDS [5]. Given the
prolonged survival and ‘‘graying’’ of the HIV-infected population,
it is possible that the CD8+ T cell defects due to the infection may
synergize with similar defects associated with aging, further
highlighting the critical need for more precise characterization of
this subset.
Based on the significant increase in CD8+ T cells with markers
of senescence in HIV-infected persons, the current study focused
on several novel markers of replicative senescence (ADA, GLUT 1
and LRRN3) to determine their relationship to the elevated CD38
expression that has been significantly linked to adverse outcomes
in HIV disease [6]. CD38 is a multifunctional ectoenzyme
involved in the regulation of intracellular calcium. Loss of CD38
function is associated with impaired immune responses and
metabolic disturbances, while increased CD38 surface expression
is a marker of immune activation that has been linked not only to
HIV, but also to B cell malignancies, solid tumors and type 2
diabetes [7].
Among the markers to be tested, adenosine deaminase (ADA),
an ectoenzyme present on T cells, seemed particularly relevant to
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HIV disease, since it functions to convert immunosuppressive
adenosine to inosine. Adenosine not only inhibits multiple T cell
functions, including IL-2 production [8,9,10], but also accelerates
the generation of senescent T cells and loss of CD28 in cell culture
[11]. ADA also enhances CD28 costimulation by amplifying the
immunological signaling through its binding to CD26 on antigen-
presenting cells. (Interestingly, in HIV-infected persons, ADA
binding to CD26 is inhibited by HIV glycoproteins and viral
particles [12,13]). Importantly, our recent studies demonstrated
that CD8+CD28+ T lymphocytes lacking ADA surface expression
(i.e.,ecto-ADA) have significantly less telomerase activity than
those that do express ADA, and that ADA surface receptor
expression continuously declines during the progression of T cells
to senescence in cell culture [11]. Expression of the GLUT 1
receptor, which regulates T cell glucose uptake, is modulated by
CD28 [14,15]. Like ADA, its expression declines in parallel with
the transition of chronically activated CD8+ T cells to the end
stage of senescence in culture, and the decline coincides with
reduced gene expression of key enzymes involved in gluconeo-
genesis and glycolysis. The third novel biomarker selected for
analysis with respect to CD8+ T cells in HIV disease is the
Leucine-Rich Repeat Neuronal 3 gene (LRRN3), the expression of
which declines in senescent CD8+ T cell cultures, and in ex vivo
purified senescent CD8+ T cells from HIV-infected persons
(unpublished data). Importantly, causal network analysis [16] of
gene expression data from multiple independent aging studies
suggests that LRRN3 lies upstream of CD28 (Horvath,S., Effros,
R.B., manuscript in preparation).
Here, we present our initial studies on T cells from 48 HIV-
infected men, and show that ADA and LRRN3, as well as
telomerase activity, strongly correlate with CD8+ T cell activation
status as measured by CD38 and HLA-DR surface expression.
Our analysis revealed that among the markers tested, ADA
expression showed the strongest association, independent of a
variety of confounding factors. There was no association detected
between activation markers and the GLUT 1 glucose transporter.
Materials and Methods
Ethics Statement
All study participants from the cross-sectional study were
recruited from the Los Angeles area. This study was approved
by the University of California, Los Angeles Medical Institutional
Review Board and each participant provided written, informed
consent per the approved protocol.
Human Subjects
HIV+ males, who are participants in the UCLA Multicenter
AIDS Cohort Study (MACS) provided peripheral blood samples
during their routine MACS Clinic visit. At the time of the visit,
clinical information was obtained and confirmed by medical
record review. Data on HIV-1 serostatus, absolute CD4+ T-cell
counts, and plasma HIV viral load were collected. All participants
are on combination antiretroviral therapy. Table 1 summarizes
the clinical data of the study participants.
Cell isolation and activation
Fresh peripheral blood was acquired by venipuncture. Follow-
ing Ficoll-Hypaque gradient centrifugation, the PBMC layer was
carefully removed and washed twice in complete RPMI 1640
(10% FBS, 10 mM HEPES, 2 mM glutamine, 50 IU/ml penicil-
lin/streptomycin). For LRRN3 studies, CD8+ T cells were isolated
immediately after Ficoll-Hypaque centrifugation, using the Easy-
Sep CD8 enrichment kit (Stemcell Technologies, Vancouver,
British Columbia, Canada). For the telomerase activity assay, cell
activation was necessary, since our previous studies indicated that
telomerase is undetectable in ex vivo isolated CD8+ T cells from
HIV-infected persons. Accordingly, PBMCs were exposed for
72 hours to T cell activation microbeads (anti-CD2/3/28;
Miltenyi Biotec, Auburn, CA), with 10 ml microbead mixture
added for every 16106 cells, and CD3+ and CD8+ T cells were
isolated using EasySep human T cell or CD8+ enrichment kits
(Stemcell Technologies, Vancouver, British Columbia, Canada).
For flow cytometry experiments, PBMCs were cultured for
72 hours with irradiated (8000 rad) allogeneic transformed B
lymphoblastoid cells in complete RPMI 1640 supplemented with
recombinant IL-2 (10 U/ml), as previously described [17]. For all
cultures, viable cell concentration was routinely .90%, as
determined by trypan blue exclusion. Purity of the CD8+ T cells
was verified by flow cytometry and was routinely.95%. For these
studies, rather than separating only the HIV-1-specific CD8+ T
cells, we isolated total CD8+ T cells, because that allowed us to
capture information on CD8+ T cells of multiple specificities,
which are putatively being chronically stimulated by the inflam-
matory milieu, and/or by other latent viruses, such as EBV and
CMV.
Flow cytometry
Surface expression of CD8, CD3, CD28, GLUT1, and ADA
was examined by immunostaining and flow cytometry. Cells were
incubated with FITC-conjugated anti-GLUT1 (R&D Systems,
Minneapolis, MN), PE-conjugated anti-CD28, APC-conjugated
anti-CD3, and PerCP-conjugated anti-CD8 (BD Biosciences, San
Jose, CA), or FITC-conjugated anti-CD3, PE-conjugated anti-
CD28, anti-ADA biotinylated (Abcam, Cambridge, MA) with
strepavidin-PerCP, and APC-conjugated anti-CD3 (BD Biosci-
ences, San Jose, CA) mAbs at 4uC for 20 min, washed, and fixed
in PBS containing 1% paraformaldehyde. Staining with primary
and secondary mAbs alone was included as controls for ADA, to
ensure exclusion of non-specific or background fluorescence.
Parallel samples were incubated with Ig isotype control Abs or
Table 1. Age and Clinical Features of Study Participants
(N= 48).
Demographic Characteristics Mean Range
Mean age (SD) 57.5 (6.4) 41–67 years
Duration of Infection (SD) 22.9 (5.3) 7.3–25.6 years
AIDS diagnosis (% total) 11 (23%)
%CD4 positive (SD) 31.4% (9.1) 11–51%
Viral Load in copies/mL 10* Undetectable
(10) -9580
Other diagnostic diseases # cases (% of total)
Wasting Syndrome 4 (8.3%)
Pneumocystis pnemonia 2 (4.2%)
Crytosporidiosis 1 (2.1%)
Pulmonary tuberculosis 1 (2.1%)
Non-hodgkin’s lymphoma 1 (2.1%)
Candida esophagitis 1 (2.1%)
Multiple AIDS diagnosis 1 (2.1%)
All participants are on combination antiretroviral therapy.
*The median is provided because there were a few outliers with very high viral
load.
doi:10.1371/journal.pone.0064702.t001
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secondary Abs (BD Biosciences). All samples were analyzed on a
FACS Calibur flow cytometer (BD Biosciences). Fluorescence data
from at least 25,000 cells were acquired. The lymphocyte
population was gated on, and within that population, CD3,
CD28, CD8, GLUT1 and ADA positive fluorescence were
assessed, taking into account non-specific isotype staining and
appropriate primary and secondary control stains. Analysis of data
was performed using CellQuest Pro (BD Biosciences). We included
samples from two healthy subjects in our flow cytometry analysis,
and, as expected they showed no staining with the activation
markers, and positive staining for GLUT 1 and ADA.
Telomerase activity measurements
Telomerase activity was determined using a modified version of
the Telomerase Repeat Amplification Protocol (TRAP), as
previously described [18], Briefly, for each sample 16106 CD3+
or CD3+CD8+ cells were pelleted and washed twice with PBS.
Cell pellets were lysed in 100 uL of M-PER Mammalian Protein
Extraction Reagent (Pierce, Rockford IL) and incubated on ice for
1 hour. To control for slight inter-sample cell number variance,
samples were normalized according to nucleic acid concentration,
which was determined using the Quant-iT Ribogreen RNA Assay
Kit (Molecular Probes). The endogenous telomerase present in the
cell extract adds telomeric repeats to the telomerase substrate (TS),
a nontelomeric oligonucleotide. The extension products are then
amplified several-fold by the polymerase chain reaction (PCR)
carried out by Taq polymerase using a Cy-5-labeled forward primer
(known as TS: 59-/5Cy5/AATCCGTCGACGCAGAGTT) as a
substrate for telomerase-mediated addition of TTAGGG repeats,
and an anchored reverse primer (ACX 59-GCGCCGCTTAC
CCTTACCCTTACCCTAACC-39). To measure the telomerase
activity, each sample was mixed with 20 ul of Bromothenol Blue
loading dye, and 35 ul of sample + dye and was loaded and run
using 10% non-denaturing PAGE in 16TBE buffer. Gels were
run at approximately 300 V for 80 min, and each sample was
evaluated at least two times on separate gels. Gels were scanned on
a STORM 865 (GE Healthcare, Piscataway, NJ) and quantified
using the software ImageQuant 5.2, which integrates signal
intensity over the telomere length distribution on the gel as a
function of molecular weight (GE Healthcare, Piscataway, NJ).
Real-Time Quantitative Polymerase Chain Reaction of
LRRN3
RNA was isolated using the Qiagen RNAeasy kit (Qiagen,
Valencia, CA), and quantified using the Quant-iT Ribogreen
RNA Assay Kit (Molecular Probes). cDNA was synthesized with
the iScript cDNA synthesis kit (Bio-Rad) using 300 ng RNA. Real-
time quantitative polymerase chain reaction assays were per-
formed using the SsoFast EvaGreen dye (Bio-Rad) and samples
run on CFX96 (Bio-Rad), using 36B4 as an internal control. The
sequences were designed with the aid of Primer 3 software and
synthesized by Integrated DNA Technologies, Inc., Coralville,
IA. LRRN3: sense TCCTTACCTAGACAATGAGAAGAGCA
ATC, antisense CCACCAACCACCACCAGCAC; 36B4: sense
CAGGCT-AACTACTCGCTCAACACAG; antisense TGTC
CCGTTTGGTCATCTGGTAATC.
Statistical Methods
Correlation was assessed by Pearson correlation. Linear
regression was performed controlling for the following confound-
ers: log viremia, CD4+ T cell count, an indicator whether the
patient has been diagnosed with an AIDS-defining opportunistic
infection, and age. Viral load measures were log 10 transformed
prior to analysis. Analyses were performed in SAS version 9.2
(Cary, NC) and R for Mac version 2.15.
Results
ADA expression is inversely correlated with CD8+ T cell
activation markers
PBMCs were isolated from 48 HIV-1+ individuals and the
extracellular phenotypes of CD8+ T cells within these populations
were investigated by flow cytometry. Using the Pearson Correla-
tion model, we found that persons with the lowest percentage of
ADA on total CD8+ T cells had the highest number of surface
CD38 and HLA-DR molecules, as well as the highest percentage
of CD8+ T cells that were positive for both activation markers
(fig. 1a-1c). Furthermore, consistent with our previous in vitro
studies on T cells from HIV-infected donors, which documented
the highest telomerase activity in those CD8+CD28+ T cells that
also expressed ADA [11], the current analysis shows that CD8+ T
cell telomerase activity was positively correlated with the
percentage of CD8+ T cells that were ADA+ (fig. 1d,
r = 0.4012, p = 0.0069).
In addition, using regression analysis and controlling for such
confounding factors as log viremia and low CD4+ T cell counts,
the data indicate that ADA expression on CD8+ T cells could
explain nearly 53% of the variance in the levels of CD38 and
HLA-DR activation observed (p,0.0001). These activation
markers are commonly used in clinical settings to assess immune
status and the manifestation of AIDS. We conclude from our
results that loss of ecto-ADA on CD8+ T cells may reflect a more
senescent and dysfunctional phenotype, and that HIV-infected
persons with low ADA expression on their CD8+ T cells may
undergo a more rapid progression to AIDS. Therefore, inclusion
of surface ADA expression analysis in the assessment of immune
status during chronic HIV-1 infection may provide a new,
biologically meaningful clinical metric, particularly with respect
to its role in enhancing telomerase activity.
Higher LRRN3 gene expression correlates with a less
senescent T cell phenotype
Gene expression of LRRN3 was inversely correlated with the
percentage of CD38+HLA-DR+CD8+ T cells (fig. 2a,
r =20.36012, p= 0.0192). Furthermore, LRRN3 expression was
strongly positively correlated with telomerase activity of T cells
(fig. 2b, r = 0.5988 p=0.0002), underscoring the potential upstream
regulatory role of LRRN3 in T cell functionality. In that regard, our
data show that the level of LRRN3 mRNA was also positively
correlated (fig. 2c, r = 0.3782, p= 0.0161) with the percentage of
CD8+ that express CD28, a key costimulatory receptor required for
optimal T cell activation, telomerase upregulation, signal transduc-
tion and function [19,20,21]. Since irreversible loss of CD28 gene
expression is one of the key characteristics of senescence, this
positive association highlights a possible immunological interaction
between these genes, and suggests that expression of LRRN3, like
CD28, is important for the prevention of acquiring features of
senescence. Thus, our data support the hypothesis that sustained
expression of LRRN3 may function to maintain normal T cell
function during chronic antigenic stimulation, similar to our
observations regarding telomerase [22].
High CD38 expression was strongly associated with
reduced telomerase activity
Our analysis of telomerase activity accords with studies by
Lichterfeld et al. [23], showing that CD8+ T cells from HIV-1
Novel Biomarkers of Senescent T Cells in HIV/AIDS
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controllers have long telomeres and high levels of constitutive
telomerase activity, while the opposite phenotype characterizes T
cells from progressors. Indeed, we observed that T cells from
individuals with a high percentage of CD8+ T cells that were
strongly positive for CD38 and HLA-DR had significantly lower
telomerase activity than T cells with low levels of these activation
markers. Fig. 3a is a representative TRAP gel showing CD8+ T
cell telomerase activity from two donors, one with high, and one
with low percentages of CD8+ T cells that were CD38+. Our
collective data set documents a strong negative relationship
between the proportion of activated (CD38+HLA2DR+) T cells
and telomerase activity of total (CD3+) T cells (fig. 3c,
r =20.5531, p= 0.0001). Moreover, as noted above, there was a
strong association between ADA expression and CD3+ T cell
telomerase activity (not shown, r = 0.6511; p,0.0001), further
underscoring the importance of ADA in modulating telomerase, as
proposed by Parish et al. [11]. Reduced telomerase activity is a
well-established marker of senescence in aging and HIV-1
infection both in vitro and in vivo [23,24,25]. Thus, the reduced
telomerase activity observed in the HIV-1-infected MACS donors
with high percentages of CD38 and HLA-DR within our sampling
group supports our overarching hypothesis that chronic activation
is a strong driver of the progression of CD8+ T cells along the
trajectory to replicative senescence. These data add to the
accumulating evidence that the process of replicative senescence,
which affects multiple facets of human aging, also contributes to
the overall adaptive immune system dysfunction during HIV-1
infection.
Discussion
The major finding of the current study relates to ADA, which
when complexed to CD26 on antigen-presenting cells, constitutes
a key costimulatory component of the immunological synapse.
Our analysis provides the first demonstration that ADA is
significantly reduced in CD8+ T cells from those HIV-1-infected
individuals with high CD38 expression, a biomarker of immune
activation. This observation is consistent with extensive data on
loss of ADA expression caused by chronic activation of CD8+ T
cells in cell culture [11]. Using regression analysis, ADA positivity
was also found to serve as the strongest variable among our
biomarkers that accounts for more than half of variation of
expression of CD38+HLA-DR+, markers frequently used in
clinical settings to evaluate HIV disease progression. In addition,
since ADA is essential for optimal telomerase activity in CD8+ T
lymphocytes [11], the results of this study, indicating the inverse
relationship between CD38 and T cell telomerase activity, may
support the upstream stimulatory function of ADA on telomerase
Figure 1. Low ecto-ADA expression correlates with high levels of activation markers. (a) Representative flow cytometry data of surface
staining for ecto-ADA and CD8 molecules on T cells 4 days after stimulation with an allogeneic transformed B-cell line. Comparison between %ADA+
within the CD8+ T cell subset from HIV+ donors with low (top) and high activation (bottom) levels, defined by activation marker CD38 (2.1% and
18.2%, respectively). CD8+ T cells with low %CD38 had greater ecto-ADA expression (30.2%), as compared to those with high %CD38, who showed
lower ADA (13.3%). (b) Representative histogram comparing the same donors as in panel (a). The dark lines represent the donor with high activation
(18.2%), compared to the donor with low activation (2.1%). (c) Statistical analyses indicating a strong negative relationship between ecto-ADA
expression and percentages of CD38+ and HLA-DR+ (r =20.5441, p,0.0001), as well as number of CD38 molecules (r =20.4766, p = 0.0004). (d)
Significant positive correlation between CD8+ADA+ and CD8+ telomerase activity (r = 0.4012, p,0.0069).
doi:10.1371/journal.pone.0064702.g001
Novel Biomarkers of Senescent T Cells in HIV/AIDS
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e64702
activity. This observation has important in vivo consequences, since
T cells lacking ADA are vulnerable to adenosine, an immuno-
suppressive factor produced by certain Tregs and present in the
microenvironment of many tumors [26]. Moreover, exposure of
CD8+ T cells to adenosine in cell culture accelerates many of the
changes associated with senescence, such as reduced proliferative
potential, diminished IL-2 message, and early loss of both CD28
expression and telomerase activity [11].
Our study also demonstrates strong associations between
telomerase activity, LRRN3 gene expression and CD38 levels,
and may therefore establish a novel panel of parameters that can
be used in future clinical evaluation of our hypothesis. Together,
the data provide a more definitive picture of the dysfunctional
CD8+ T cell compartment in HIV-infected persons. Indeed,
further refining of the genetic and molecular signature of senescent
CD8+ T cells in the HIV-1-infected population may be beneficial
in assisting clinicians to strategize the course and intensity of ART
treatment for individual patients. Interestingly, although GLUT 1
expression and glucose uptake in T cells are both modulated by
CD28, our analysis failed to show any association between GLUT
1 expression and CD8+ T cell activation.
The accumulation of senescent CD8+ T cells affects not only
immune function, but may also impact other physiological
systems. Indeed, a recent study by Kaplan et al. [27] showed
that frequencies of both highly activated (i.e., CD8+CD38+HLA-
DR+) and senescent (i.e., CD8+CD282CD57+) T cells in HIV-1-
infected women were associated with increased prevalence of
carotid artery lesions. It was concluded that HIV-associated T cell
changes, characterized by specific senescence and activation
markers, are associated with subclinical carotid artery abnormal-
ities, which are observed even among those patients achieving viral
suppression with effective ART [27]. Collectively, those results,
Figure 2. LRRN3 mRNA expression is associated with increased expression of CD38+ and HLA-DR+. (a) Ex vivo CD8+ T cells from HIV+
donors were isolated using RosetteSep CD8+ T cell enrichment cocktail from whole blood. LRRN3 transcription in CD8+ T cells was compared for HIV+
donors with high and low levels of activation, defined by CD38 and HLA-DR. 36B4 was used as the housekeeping gene. There was a strong negative
relationship between LRRN3 mRNA and percentages of CD38+ and HLA-DR+ cells (r =20.36012, p = 0.0192). (b) Positive correlation between LRRN3
mRNA and CD3+ telomerase activity (r = 0.5988, p,0.0001) and CD8+ telomerase activity (r = 0.2724, p = 0.11). (c) Positive relationship between LRRN3
mRNA and %CD28+ within the CD8+ T cell subset (r = 0.3782, p = 0.0161), suggesting a potential modulatory role of LRRN3 on CD28 surface
expression.
doi:10.1371/journal.pone.0064702.g002
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coupled with our own findings, provide compelling evidence for
the importance of incorporating CD*+ T cell senescence-related
biomarkers in both the clinical evaluation of immune status and in
determining risk factors for age-related pathologies that are
occurring with increasing frequency in the context of HIV disease.
In sum, these initial observations on novel molecular and
genetic changes occurring as CD8+ T cells progress toward the
end stage of senescence in HIV-1 infected persons highlight the
need for more comprehensive in vitro proof-of-principle and
functional analyses of the causal role of these markers in the
generation of senescent CD8+ T cells. Gene therapy with viral
vectors encoding ADA, LRRN3 and/or hTERT, the catalytic
subunit of human telomerase, as well as testing small molecules
that upregulate enzymatic or transcriptional activity of these genes
may lead to further elucidation of critical new pathways involved
in the process of cellular senescence. Current research in our lab is
addressing these issues, with the goal of developing fresh
therapeutic approaches to rejuvenating immune function of
CD8+ T cells, in order to enhance the health span of the aging
HIV-1-infected population.
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